Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.

[1]  A. Gown,et al.  BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas , 2016, The American journal of surgical pathology.

[2]  D. Ettinger,et al.  Malignant pleural mesothelioma. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  A. Husain,et al.  BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. , 2015, Human pathology.

[4]  G. Rossi,et al.  BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations , 2015, Modern Pathology.

[5]  S. Miyamoto,et al.  p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. , 2015, American journal of clinical pathology.

[6]  M. Becich,et al.  High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  Y. Matsuno,et al.  Morphology of 9p21 homozygous deletion‐positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology , 2013, Cancer cytopathology.

[8]  A. Gown,et al.  Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. , 2013, Archives of pathology & laboratory medicine.

[9]  A. Nonomura,et al.  Genomic gains and losses in malignant mesothelioma demonstrated by FISH analysis of paraffin-embedded tissues , 2011, Journal of Clinical Pathology.

[10]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[11]  C. Sander,et al.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma , 2011, Nature Genetics.

[12]  A. Krasinskas,et al.  The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations. , 2011, American journal of clinical pathology.

[13]  M. Tsao,et al.  FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma , 2010, Journal of Clinical Pathology.

[14]  A. Nonomura,et al.  9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis , 2010, Pathology international.

[15]  F. Galateau-Sallé,et al.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma , 2009, European Respiratory Journal.

[16]  Erwin G. Van Meir,et al.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. , 2008, Cancer research.

[17]  Simion I. Chiosea,et al.  Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas , 2008, Modern Pathology.

[18]  BTS statement on malignant mesothelioma in the UK, 2007 , 2007, Thorax.

[19]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Rogers.  Spencer's pathology of the lung , 1999, Histopathology.

[21]  M. Tagawa,et al.  Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. , 2013, American journal of clinical pathology.

[22]  V. Roggli,et al.  Pathology of Asbestos-Associated Diseases , 2004, Springer New York.

[23]  G. Hillerdal.  Tumours of the pleura. , 1999 .